Related Experiment Video
Updated: May 10, 2025
08:14
Characterization of Leukocyte-platelet Rich Fibrin, A Novel Biomaterial
Published on: September 29, 2015
12.9K
Advanced Platelet-Rich Fibrin Plus (A-PRF+) as an Additive to Hard Tissue Managing Protocols in Oral Surgery: A
Marek Chmielewski1, Andrea Pilloni2, Paulina Adamska3
1Private Dental Practice, 14 Kolberga Street, 81-881 Sopot, Poland.
Journal of Functional Biomaterials
|April 25, 2025
Summary
Advanced platelet-rich fibrin plus (A-PRF+) enhances hard tissue regeneration and implant stability in dentistry. This autologous material improves bone healing and integration with biomaterials, offering a patient-friendly alternative.
Area of Science:
- Regenerative Medicine
- Biomaterials Science
- Oral and Maxillofacial Surgery
Background:
- Advanced Platelet-Rich Fibrin plus (A-PRF+) is a third-generation autologous platelet derivative.
- It releases growth factors to promote tissue healing.
- This review focuses on A-PRF+'s effectiveness in hard tissue procedures.
Purpose of the Study:
- To review the literature on the effectiveness of A-PRF+ in hard tissue regeneration.
- To evaluate A-PRF+'s impact on bone healing and implant stability in dentistry.
Main Methods:
- Included randomized clinical trials comparing A-PRF+ in bone regeneration/healing in dentistry.
- Searched PubMed, Scopus, Google Scholar, and Cochrane databases (2014-2024).
- Qualified 10 articles focusing on A-PRF+.
Main Results:
- A-PRF+ increased vertical and horizontal alveolar ridge dimensions and bone volume.
- It enhanced biomaterial integration and primary implant stability.
- A-PRF+ improved periodontal defect treatment outcomes.
Conclusions:
- A-PRF+ addition significantly enhances bone healing and integration with biomaterials.
- It increases implant insertion torque, improving primary and secondary stability.
- A-PRF+ is a viable alternative to human- and animal-derived biomaterials.
Related Concept Videos
01:22Formation of the Platelet Plug
2.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
2.8K
01:16Clot Retraction and Fibrinolysis
2.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
2.5K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
388
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
388